Ekzoticheskie virusnye gepatity (obzor literatury)

References

1. 1. WHO publishes list of top emerging diseases likely to cause major epidemics [Electronic resource]. – Access mode: https://www.who.int/news/item/10-12-2015-who-publishes-list-of-top-emerging-diseases-likely-to-cause-major-epidemics (дата обращения: 26.05.2024).
2. 2. Asogun D.A., Günther S., Akpede G.O. [et al.] Lassa fever: epidemiology, clinical features, diagnosis, management and prevention // Infect Dis Clin North Am. 2019. 33 (4). P.933–951. https://doi.org/10.1016/j.idc.2019.08.002. EDN: MWJFYP
3. 3. Avšič-Županc T., Saksida A., Korva M. Hantavirus infections // Clin Microbiol Infect. 2019. 21S. P. e6-e16.
4. 4. Bailey A.L., Kang L.I. [et al.] Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury // Proc Natl Acad Sci U S A. 2020. 117(51). P. 32648–32656. https://doi.org/10.1073/pnas.2014096117. EDN: SHRJDY
5. 5. Beck H, Guzman L., Li B. [et al.] Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa // PLoS Negl Trop Dis. 2013. 7(3). Article e1910.
6. 6. Bell-Kareem A.R., Smither A.R. Epidemiology of Lassa fever // Curr Top Microbiol Immunol. 2021.
7. 7. Bente D.A., Forrester N.L., Watts D.M. [et al.] Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity // Antivir Res. 2013. 100 (1). P. 159–189. https://doi.org/10.1016/j.antiviral.2013.07.006. EDN: SQNLIX
8. 8. Bereczky S., Lindegren G., Karlberg H. [et al.] Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice // J. Gen Virol. 2010. 91(6). P. 1473–1477. https://doi.org/10.1099/vir.0.019034-0. EDN: VGQHZR
9. 9. Dungu B., Lubisi B.A., Ikegami T. Rift Valley fever vaccines: current and future needs // Curr Opin Virol. 2018. 29. P. 8–15. https://doi.org/10.1016/j.coviro.2018.02.001. EDN: YFSLXF
10. 10. Fausther-Bovendo H., Qiu X., He S. [et al.] NK cells accumulate in infected tissues and contribute to pathogenicity of Ebola virus in mice // J Virol. 2019. 93 (10).
11. 11. Feldmann H., Sprecher A., Geisbert T.W. Ebola // Med. 2020. 382 (19). P. 1832–1842.
12. 12. Garrison A.R., Smith D.R., Golden J.W. Animal models for crimean-Congo hemorrhagic fever human disease // Viruses. 2019. 11 (7).
13. 13. Goeijenbier M., Wagenaar J., Goris M. [et al.] Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable – epidemiology, diagnostics and treatment // Crit Rev Microbiol. 2013. 39 (1). P. 26–42. https://doi.org/10.3109/1040841X.2012.686481. EDN: RMDPNT
14. 14. Guzman M.G., Harris E. Dengue // Lancet. 2015. 385 (9966). P. 453–465.
15. 15. Halstead S., Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management // Travel Med. 2019. 26 (7). P. 1–15.
16. 16. Hawman D.W., Ahlén G., Appelberg K.S. [et al.] A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model // Nat Microbiol. 2021. 6 (2). P. 187–195.
17. 17. Iroezindu M.O., Unigwe U.S., Okwara C.C. [et al.] Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa // Trop Med Int Health, 2015. 20 (11). P. 1424–1430.
18. 18. Javelle E., Lesueur A., Pommier De Santi V. [et al.] The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal // Ann Clin Microbiol Antimicrob. 2020. 19(1).
19. 19. Katzelnick L.C., Gresh L., Halloran M.E. [et al.] Antibody-dependent enhancement of severe dengue disease in humans // Science. 2017. 358 (6365). [ 929–932.
20. 20. Merson L., Bourner J., Jalloh S. [et al.] Clinical characterization of Lassa fever: a systematic review of clinical reports and research to inform clinical trial design // PLoS Negl Trop Dis. 2021. 15 (9). Article e0009788.
21. 21. Monath T.P., Vasconcelos P.F. Yellow fever // J. Clin Virol. 2015. 64. P. 160–173.
22. 22. Noack D., Goeijenbier M., Reusken C. [et al.] Orthohantavirus pathogenesis and cell tropism // Front Cell Infect Microbiol. 2020. 10. P. 399. https://doi.org/10.3389/fcimb.2020.00399. EDN: WGVRRW
23. 23. Odendaal L., Davis A.S., Venter E.H. Insights into the pathogenesis of viral haemorrhagic fever based on virus tropism and tissue lesions of natural Rift Valley fever // Viruses. 2021. 13 (4).
24. 24. Paessler S., Walker D.H. Pathogenesis of the viral hemorrhagic fevers // Annu Rev Pathol. 2013. 8. P. 411–440. https://doi.org/10.1146/annurev-pathol-020712-164041. EDN: RIGIYB
25. 25. Pattyn S., van der Groen G., Jacob W. [et al.] Courteille Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire // Lancet. 1977. 1 (8011). P. 573–574.
26. 26. Prevention CfDCa Dengue around the world CDC, 2021, updated 19–11–2021 [Electronic resource]. – Access mode: https://www.cdc.gov/dengue/areaswithrisk/around-the-world.html
27. 27. Raafat N., Blacksell S.D., Maude R.J. A review of dengue diagnostics and implications for surveillance and control // Trans R Soc Trop Med Hyg. 2019. 113 (11). P. 653–660.
28. 28. Richards G.A., Baker T., Amin P. Ebola virus disease: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine // Crit Care. 2018. 43. P. 352–355.
29. 29. Teerasarntipan T., Chaiteerakij R., Komolmit P. [et al.] Acute liver failure and death predictors in patients with dengue-induced severe hepatitis // World J Gastroenterol. 2020. 26 (33). P. 4983–4995.
30. 30. van Leeuwen LPM, de Jong W., Doornekamp L. [et al.] Exotic viral hepatitis: A review on epidemiology, pathogenesis, and treatment. J Hepatol. 2022 Nov; 77(5): 1431–1443.
31. 31. Vieira V., Pacheco L., Demetrio L. [et al.] Liver transplantation for acute liver failure due to yellow fever: a case report // Transpl Proc. 2019. 51 (5). P. 1625–1628.
32. 32. Voysey M., Clemens S.A.C., Madhi S.A. [et al.] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK // Lancet. 2021. 397 (10269). P. 99–111.
33. 33. WHO Ebola virus disease (2021) updated 23–02–2021 [Electronic resource]. – Access mode: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
34. 34. Wolf T., Ellwanger R., Goetsch U. [et al.] Fifty years of imported Lassa fever: a systematic review of primary and secondary cases // Travel Med. 2020. 27 (4).
35. 35. Wright D., Kortekaas J., Bowden T.A., Warimwe G.M. Rift valley fever: biology and epidemiology // Gen Virol. 2019. 100(8). P. 1187–1199.